Oculis Holding AG (NASDAQ:OCS – Get Free Report)’s stock price fell 9.6% on Thursday after JPMorgan Chase & Co. lowered their price target on the stock from $42.00 to $23.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Oculis traded as low as $12.06 and last traded at $11.8770. 241,820 shares traded hands during trading, a decline of 49% from the average session volume of 476,665 shares. The stock had previously closed at $13.14.
OCS has been the subject of several other reports. Needham & Company LLC cut their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. Stifel Nicolaus cut their price objective on Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Guggenheim decreased their target price on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a report on Monday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and a consensus price target of $38.33.
Read Our Latest Stock Analysis on OCS
Institutional Inflows and Outflows
Oculis Stock Performance
The firm has a 50-day simple moving average of $26.98 and a two-hundred day simple moving average of $25.09. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $679.58 million, a price-to-earnings ratio of -5.55 and a beta of 0.23.
Oculis (NASDAQ:OCS – Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. As a group, sell-side analysts forecast that Oculis Holding AG will post -2.23 earnings per share for the current fiscal year.
Oculis Company Profile
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Oculis
- The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker
- Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
- Gen Z Trends Make These 3 Stocks Worth Watching
- How the Memory Shortage Is Crushing the Gaming Industry
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
